AIT-102

About OrphAI Therapeutics

OrphAI Therapeutics is a private, preclinical to Phase 2 biotech founded in 2020 and headquartered in New Haven, Connecticut. The company is advancing a focused pipeline led by LAM-001, a candidate in Phase 2 for Bronchiolitis Obliterans Syndrome (BOS) and earlier stages for pulmonary hypertension-associated disorders, alongside earlier-stage oncology and neurology programs. Utilizing an AI/ML-driven discovery platform, OrphAI aims to develop life-saving drugs for niche, underserved patient populations, operating as a pre-revenue entity with a lean, experienced leadership team.

Therapeutic Areas